IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Mary Ellen Rybak, et al.	Examiner: Anne L. Holleran
Serial No.: 09/904,263	Group Art Unit: 1642
Filed: July 12, 2001	Atty. Docket No.: OC01000KQ
For: MELANOMA THERAPY	

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

(a) Pursuant to Rule 56, it is requested that the documents listed on the accompanying PTO-1449 Form be considered and made of record in the above-identified patent application. Copy(ies) of these references ☒ are attached ☐ were filed in related application U.S. Serial No(s) _____ filed _____, respectively.

(b) ☒ No fee is believed due because:

- ☐ This Information Disclosure Statement is being filed within three (3) months of the filing date of the application.
- ☐ This Information Disclosure Statement is being concurrently filed with the above-identified application.
- ☒ This Information Disclosure Statement is being concurrently filed with a Request for Continued Examination (RCE).
- ☐ This Information Disclosure Statement is being filed prior to the mailing of a first Office Action on the merits.

(c) ☐ This Information Disclosure Statement is being filed before the mailing date of any final action, notice of allowance or an action that otherwise closes prosecution; and

- ☐ Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ The Commissioner is hereby authorized to charge the requisite fee listed on the attached Fee Transmittal Sheet.

(d) ☐ This Information Disclosure Statement is being filed on or before the payment of the issue fee; and

☐ Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or

☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement; and

☐ The Commissioner is hereby authorized to charge the requisite fee listed on the attached Fee Transmittal Sheet.

☒ The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. **19-0365**, Patent Case No. **OC01000KQ**. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,

SCHERING-PLOUGH CORPORATION

Dated: **March 22, 2004** By: Karen E. Brown
Karen E. Brown

SCHERING-PLOUGH CORPORATION
Patent Department, K-6-1, 1990
2000 Galloping Hill Road
Kenilworth, NJ 07033-0530
Facsimile No.: (908) 298-5388

Name: **Karen E. Brown**
Reg. No.: **43,866**
Attorney of Record
Telephone No.: (908) 298-2902

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: OC01000KQ	APPLICATION NO.: 09/904,263
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT: Mary Ellen Rybak, et al.	
(Use several sheets if necessary)	FILING DATE: 07/12/2001	GROUP: 1642

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES	TRANSLATION NO

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	AA	Bruno, René, *et al.*, "Population Pharmacokinetics/Pharmacodynamics of Docetaxel in Phase II Studies in Patients with Cancer," *Journal of Clinical Oncology* **16(1)**:187-96 (1998)
	AB	Calvert, A.H., *et al.*, "Carboplatin Dosage: Prospective Evaluation of a Simple Formula Based on Renal Function," *Journal of Clinical Oncology* **7(11)**:1748-56 (1989)
	AC	Eisenhauer, Elizabeth A., *et al.*, "The Taxoids, Comparative Clinical Pharmacology and Therapeutic Potential," *Drugs* **55(1)**:5-30 (1998)
	AD	Eksborg, Steffan, *et al.*, "Plasma pharmacokinetics of idarubicin and its 13-dihydro metabolite-a comparison of bolus versus 2 h infusion during a 3 day course," *Anti-Cancer Drugs* **8**:42-7 (1997)
	AE	Forastiere, Arlene A., *et al.*, "Pharmacokinetic and Toxicity Evaluation of Five-Day Continuous Infusion *versus* Intermittent Bolus *cis*-Diamminedichloroplatinum(II) in Head and Neck Cancer Patients," *Cancer Research* **48**:3869-3874 (1988)
	AF	Gandhi, Varsha, *et al.*, "Compound GW506U78 in Refractory Hematologic Malignancies: Relationship Between Cellular Pharmacokinetics and Clinical Response," *Journal of Clinical Oncology* **16(11)**:3607-15 (1998)
	AG	Rodman, John H., *et al.*, "Clinical Pharmacodynamics of Continuous Infusion Teniposide: Systemic Exposure as a Determinant of Response in a Phase I Trial," *Journal of Clinical Oncology* **5(7)**:1007-1014 (1987)
	AH	Shalinsky, David R., *et al.*, "Antitumor efficacy of AG3340 associated with maintenance of minimum effective plasma concentrations and not total daily dose, exposure or peak plasma concentrations," *Investigational New Drugs* **16**:303-13 (1999)
	AI	Takitani, Kimitaka, *et al.*, "4-Oxo Retinoic Acid for Refractory Acute Promyelocytic Leukemia in Children with All-*Trans* Retinoic Acid Therapy," *J. Nutr. Sci. Vitaminol.* **41**:493-98 (1995)

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.